Sugi Predict

Sugi Predict / Compounds / SCHEMBL693427

SCHEMBL693427

SCHEMBL693427

CC(C)(C)OC(=O)NCCc1ccc(C=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 5/20 0.53
▸ CA1 P00915 3/20 0.53
▸ NAMPT P43490 1/20 0.52
▸ EPHX2 P34913 1/20 0.45
▸ NR1H4 Q96RI1 1/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ NQO2 P16083 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ ABCG2 Q9UNQ0 1/20 0.44
▸ PTGER4 P35408 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ IDO1 P14902 1/20 0.43
▸ CTSK P43235 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ SIGMAR1 Q99720 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694269 0.87 CA2 (0.54) CA2CA1NAMPTTDP1MAPT
SCHEMBL23051881 0.85 EPHX2 (0.42) CA2CA1NAMPTEPHX2NR1H4
SCHEMBL208544 0.85 EPHX2 (0.57) CA2CA1NAMPTEPHX2NR1H4
SCHEMBL698405 0.83 NQO2 (0.49) CA2CA1NAMPTMAPTNQO2
SCHEMBL100146 0.83 KDM4E (0.60) CA2CA1NAMPTTDP1MAPT
SCHEMBL1569661 0.83 CA2 (0.56) CA2CA1NAMPTTDP1MAPT
SCHEMBL27741035 0.83 CA2 (0.56) CA2CA1NAMPTTDP1MAPT
SCHEMBL12283041 0.83 NPC1 (0.60) CA2CA1NAMPTEPHX2TDP1
SCHEMBL1065312 0.82 CA2 (0.55) CA2CA1NAMPTTDP1MAPT
SCHEMBL21521028 0.82 CA2 (0.55) CA2CA1NAMPTTDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727552-A2 PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS Merck Sharp & Dohme LLC (US) 2026-04-22 — — EP disclosed
US-20250213700-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY FOX CHASE CHEMICAL DIVERSITY CENTER, INC. 2025-07-03 — — US disclosed
CN-119751307-A Preparation method of ilast and intermediate thereof 苏州华先医药科技有限公司 2025-04-04 — — CN disclosed
WO-2024259310-A2 PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC (US) 2024-12-19 — — WO disclosed
CN-119081450-A Namic nanometer nonlinear optical material tightly coated by dopamine type organic polymer and preparation and application thereof 同济大学 2024-12-06 — — CN disclosed
US-20230381329-A1 Zwitterion Polymer-Drug Conjugates UNIV UTAH RES FOUND (US) 2023-11-30 — — US disclosed
WO-2023225369-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY DUKE UNIVERSITY (US) 2023-11-23 — — WO disclosed
US-20230159592-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-25 — — US disclosed
US-20230159592-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-25 — — US disclosed
WO-2021127460-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2021-06-24 — — WO disclosed
US-20060252795-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2006-11-09 — — US disclosed
US-7091217-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2006-08-15 — — US disclosed
EP-1317451-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2006-08-09 — — EP disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 — — US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed
US-20040171638-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-09-02 — — US disclosed
US-6734191-B2 PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) ANORMED, INC. (CA) 2004-05-11 — — US disclosed
EP-1317451-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 — — EP disclosed
US-20030028022-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2003-02-06 — — US disclosed
WO-2002034745-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159592-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 CA2 4141/4885CA1 4496/4885NAMPT 2275/4885
US-20060252795-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR3, CCR2 CA2 4346/4885CA1 3626/4885NAMPT 1436/4885
US-20040171638-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR3, CCR2 CA2 4346/4885CA1 3626/4885NAMPT 1436/4885
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R CA2 3719/4885CA1 4236/4885NAMPT 3153/4885
US-20250213700-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY DDT, ABCG2, CES2 CA2 3100/4885CA1 2157/4885NAMPT 1293/4885
US-20030028022-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR3, CCR2 CA2 4346/4885CA1 3626/4885NAMPT 1436/4885
US-20230381329-A1 Zwitterion Polymer-Drug Conjugates ZW10, NUP205, DNPEP CA2 3287/4885CA1 1985/4885NAMPT 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.